Last reviewed · How we verify
Beraprost Sodium Modified Release
Beraprost sodium is a prostacyclin analog that acts on the IP receptor to dilate blood vessels and inhibit platelet aggregation.
Beraprost sodium is a prostacyclin analog that acts on the IP receptor to dilate blood vessels and inhibit platelet aggregation. Used for Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension.
At a glance
| Generic name | Beraprost Sodium Modified Release |
|---|---|
| Also known as | BPS-MR Tablets, 60mcg, Beraprost Sodium Modified Release Tablet, 60mcg, BPS-MR Tablets, 60 mcg, Beraprost Sodium Modified Release Tablet, 60 mcg |
| Sponsor | Lung Biotechnology PBC |
| Drug class | Prostacyclin analog |
| Target | IP receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Beraprost sodium mimics the natural prostacyclin, which binds to the prostacyclin (IP) receptor, leading to vasodilation and inhibition of platelet aggregation, thereby improving blood flow and reducing the risk of thrombosis.
Approved indications
- Pulmonary arterial hypertension
- Chronic thromboembolic pulmonary hypertension
Common side effects
- Headache
- Flushing
- Diarrhea
Key clinical trials
- Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) (PHASE2)
- A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension (PHASE3)
- Beraprost-314d Added-on to Tyvaso® (BEAT) (PHASE3)
- A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients (PHASE2)
- An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients (PHASE2)
- Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients (PHASE2)
- A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |